Table 1 Drugs with large revenue losses in 2011–2012
From: Patent watch
Drug; company | Indications | US generic entry | 2010 US sales (US$ million) | 2011 US sales (US$ million) | 2012 to Q3* US sales (US$ million) |
|---|---|---|---|---|---|
Plavix (clopidogrel); Sanofi | Prevention of cardiovascular events | May 2012 | 6,154 | 6,622 | 2,435 |
Lipitor (atorvastatin); Pfizer | Dyslipidaemia | November 2011 | 5,329 | 5,003 | 871 |
Seroquel (quetiapine); AstraZeneca | Schizophrenia and bipolar disorder | March 2012 | 3,747 | 4,123 | 1,311 |
Actos (pioglitazone); Takeda | Type 2 diabetes | August 2012 | 3,518 | 3,553 | 1,522 |
Singulair (montelukast); Merck | Asthma | August 2012 | 3,219 | 3,537 | 2,127 |
Zyprexa (olanzapine); Eli Lilly | Schizophrenia and bipolar disorder | October 2011 | 2,495 | 2,165 | 300 |
Lexapro (escitalopram); Forest | Depression and anxiety | Febuary 2012 | 2,277 | 2,369 | 355 |
TriCor (fenofibrate); Abbott | Dyslipidaemia | November 2012 | 1,355 | 1,372 | 896 |
Levaquin (levofloxacin); Johnson & Johnson | Bacterial infection | June 2011 | 1,285 | 585 | 35 |
Provigil/Sparlon (modafinil); Teva | Sleep disorders, ADHD | March 2012 | 1,124‡ | 1,159‡ | 392‡ |
*Indicates the sales in the 9-month period to the end of September 2012. ‡Indicates worldwide sales. ADHD, attention deficit hyperactivity disorder. Data provided by Sagient Research Systems. | |||||
